Damora Therapeutics
DMRA
23.22
-1.08
-4.44%
Damora Therapeutics
US · DMRA
#3109 by market cap
Listed 1970
23.22
-1.08
-4.44%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Cuts Target Price to $59Market Newswire · 2026/11/6
-
Rating change
Leerink Partners Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $51Market Newswire · 2026/5/15
-
Rating change
Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $60Market Newswire · 2026/9/25
-
Rating change
Evercore Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $46Market Newswire · 2026/3/25
-
Rating change
Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $40Market Newswire · 2026/7/30
-
Rating change
Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/6/16
-
Rating change
Jefferies Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $50Market Newswire · 2026/7/27
-
Rating change
TD Cowen Initiates Damora Therapeutics(DMRA.US) With Buy RatingMarket Newswire · 2026/6/8
-
Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/11/6
-
Rating change
LifeSci Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/9/19
-
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/11/5
-
Rating change
H.C. Wainwright Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $45Market Newswire · 2026/6/11
-
Rating change
RBC Capital Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $40Market Newswire · 2026/4/24
-
Leerink Partners Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $51Market Newswire · 2026/11/5
-
Rating change
A Quick Look at Today's Ratings for Damora Therapeutics(DMRA.US), With a Forecast Between $40 to $45Market Newswire · 2026/8/11
-
Rating change
A Quick Look at Today's Ratings for Damora Therapeutics(DMRA.US), With a Forecast Between $40 to $50Market Newswire · 2026/8/12
-
H.C. Wainwright Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/11/5
-
Rating change
Wedbush Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $35Market Newswire · 2026/5/28
-
Rating change
TD Cowen Maintains Damora Therapeutics(DMRA.US) With Buy RatingMarket Newswire · 2026/6/12
-
Rating change
Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/6/15
-
Rating change
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/6/30
-
Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/9/29
-
Rating change
H.C. Wainwright Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/8/6
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Damora Therapeutics discussion 0 comments